Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme
Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down …
Post
-
-
FDA locks down post-approval pregnancy safety data framework
The US Food and Drug Administration (FDA) has debuted its final industry guidance on collecting post-marketing safety data for both …
-
ACROBiosystems upgrades HEK293 licence solution for R&D compliance
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research …
-
BMS’ Sotyktu secures EC approval for psoriatic arthritis
Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Sotyktu (deucravacitinib) to treat active psoriatic arthritis …
-
Japan’s FY26 price revision expands G1 repricing and drives price reduction
Japan’s latest National Health Insurance (NHI) drug price revision for FY26 has now come into effect, with an average 4.02% …
-
Gilead posts positive Q1 buoyed by HIV drug growth
Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a …
-
AI-guided labs are approaching full autonomy
Taking a cue from the automotive industry, the biopharma sector has been increasingly focused on autonomous capabilities as a means …
-
Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill …
-
Construction begins on Novartis’ RLT centre in Texas, US
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step …
-
Streamline data capture and automate EHR-to-EDC data transfer
As clinical trial protocols grow more complex, so does the burden on research sites managing data collection and entry. Manual …
-
Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn
Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking …
-
Vitamin E TPGS ─ Emerging Applications in Novel Parenteral Drug Delivery Systems
Abstract d-α-Tocopheryl polyethene glycol 1000 succinate (TPGS) has long served as a safe, multifunctional excipient in oral drug delivery, where it …
-
GSK spends $1bn on rights to SiranBio’s metabolic oligonucleotide
GSK has bought the rights to SiranBio’s metabolic oligonucleotide therapy for up to $1bn, building on the company’s efforts to …
-
Podcast: Autonomous labs redefine the role of biopharma researchers
Advances in robotics and artificial intelligence (AI) are leading to a rise of autonomous biopharma labs—entities that can undertake biomedical …
-
Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing
Eli Lilly has shared plans to invest a further $4.5bn into its manufacturing presence in Indiana, taking the pharma company’s total investment into …
